

CA-ADAP Medical Advisory Committee: Formulary Review

APRIL 21, 2021

KRISTEN M. HALOSKI, PHARM.D.,
AAHIVP

MagellanRx
MANAGEMENTSM

CA-ADAP Formulary Review: AGENDA

ADAP's formulary covers antiretroviral treatment, opportunistic infection treatment, and select medications for common comorbidities among people living with HIV

At each MAC meeting several classes of therapeutics will be reviewed.

Today's meeting will focus on:

- Oral Contraception
- Medications to treat Asthma



Therapeutic Class Review

ORAL CONTRACEPTION

Oral Contraception



- ❖ The CDC estimates that ~half of all pregnancies in the US are unintended, creating increased risks for adverse maternal and fetal outcomes.
 - Pregnancy among HIV-infected women confer additional risks including the risk of mother to child transmission of HIV; therefore, the need for contraceptive use to avoid an unintended pregnancy in women with HIV is of importance.
- ❖ HIV infection doesn't preclude the use of any contraceptive method and that all women who don't currently desire pregnancy should be offered effective and appropriate contraception to reduce the incidence of an unintended pregnancy.
 - ❖ Women with HIV can use all available contraceptive methods, including the use of hormonal contraception and intrauterine devices (IUDs).
- ❖ Oral Contraceptive Formulations:
 - 1) Combined Oral Contraceptives:
 - a. Monophasic Products
 - b. Bi-phasic Products
 - c. Tri-phasic Products
 - d. Four-phasic Products
 - e. Extended Cycle Products
 - f. Continuous Cycle Products
 - 2) Progestin-Only Oral Contraceptives

Contraception Pharmacotherapy



OC Type	Label Name	Generic	CA ADAP FORMULARY
MONOPHASIC PRODUCTS (21 days active pills & 7 days inactive pills)			
Ethinyl Estradiol 20 mcg/Levonorgestrel 0.1 mg	Afirmelle-28, Aubra-28, Aubra EQ-28, Aviane-28, Balcoltra, Falmina-28, Larissia-28, Lessina-28, Levonor-eth estrad 0.1-0.02 mg, Luthera-28, Orsythia-28, Sronyx 0.1-0.02 mg, Tyblume 0.1-0.02 mg, Vienva-28	All but Balcoltra and Tyblume are generic	
Ethinyl Estradiol 20 mcg/Levonorgestrel 1 mg	Aurovelva FE, Blisovi FE, Hailey FE, Junel FE, Larin FE, Loestrin FE, Microgestin FE, Noreth-Estrad-Fe 1-0.02(21)-75, Tarina FE, Tarina FE 1-20 EQ	X	
Ethinyl Estradiol 30 mcg/Levonorgestrel 0.15 mg	Altavera-28, Ayuna-28, Chateal-28, Chateal EQ-28, Kurvelo-28, Levonor-Eth Estrad 0.15-0.03, Levora-28, Lillow-28, Marlissa-28, Portia-28	X	
Ethinyl Estradiol 30 mcg/Norgestrel 0.3 mg	Crystelle-28, Elinest-28, Low-Ogestrel-28	X	
Ethinyl Estradiol 30 mcg/Norethindrone Acetate 1.5 mg	Aurovela FE, Blisovi FE, Junel FE, Hailey FE, Larin FE, Loestrin FE, Microgestin FE, Norteth-EE-FE 0.5-0.03-0.3 mg	X	
Ethinyl Estradiol 30 mcg/Desogestrel 0.15 mg	Apri-28, Cyred-28, Cyred EQ-28, Desogest-Eth Estra 0.15-0.3 mg, Emoquette-28, Enskyce-28, Isibloom-28, Juleber-28, Kalliga-28, Reclipsen-28	X	
Ethinyl Estradiol 30 mcg/Drospirenone 3 mg	Drospirenon-EE 3-0.03 mg, Dros-EE-Levomef 3-0.03-0.451, Ocella 3 mg-0.03 mg, Safyral, Syeda-28, Tydemy 3-0.03-0.451, Yasmin-28, Zarah, Zumandimine 3-0.03 mg	X	

Contraception Pharmacotherapy



OC Type/Regimen	Label Name	Generic	CA ADAP FORMULARY
MONOPHASIC PRODUCTS (21 days active pills & 7 days inactive pills) <i>continued...</i>			
Ethinyl Estradiol 35 mcg/Ethinodiol Diacetate 1 mg	Ethinodiol-Eth Estra 1 mg-35 mg, Kelnor 1-35, Zovia 1-35, Zovia 1-35E	X	
Ethinyl Estradiol 35 mcg/Norgestimate 0.25 mg	Estarylla, Fermynor-28, Milli, Mono-Linyah-28, Norg-Ethin Estra 0.25-0.035 mg, Ortho-Cycle 28, Previfem, Sprintec-28, Nymyo 0.25-0.035 mg, Vylibra-28	X	
Ethinyl Estradiol 35 mcg/Norethindrone 0.4 mg	Balziva-28, Briellyn, Noret-Estra-Fe 0.4-0.035(21)-75, Philith, Vyfemla, Wymzya FE Chewable	X	
Ethinyl Estradiol 35 mcg/Norethindrone 0.5 mg	Necon, Nortrel, Wera	X	
Ethinyl Estradiol 35 mcg/Norethindrone 1 mg	Alyacen, Cyclofem, Dasetta, Nortrel, Pirmella	X	
Ethinyl Estradiol 50 mcg/Ethinodiol Diacetate 1 mg	Ethinodiol-Eth Estra, Kelnor	X	

Contraception Pharmacotherapy



OC Type	Label Name	Generic	CA ADAP FORMULARY
MONOPHASIC PRODUCTS (21 days active pills ONLY)			
Ethinyl Estradiol 20 mcg/Norethindrone 1 mg	Aurovela 1mg-20 mcg, Junel 1 mg-20 mcg, Larin 21 1-20, Loestrin 21 1-20, Microgestin 21 1-20, Norethind-Eth Estrad 1-0.02 mg	X	
Ethinyl Estradiol 30 mcg/Norethindrone 1.5 mg	Aurovela 21 1.5-30, Junel 1.5 mg-30 mcg, Hailey 21 1.5 mg-30 mcg, Larin 1.5 mg-30 mcg, Loestrin 21 1.5-30, Microgestin 21 1.5-30, Norethin-EE 1.5-0.03 mg (21)	X	
Ethinyl Estradiol 35 mcg/Norethindrone 1 mg	Nortrel 1-35 21	X	
MONOPHASIC PRODUCTS (24 days active pills & 4 days inactive pills)			
Ethinyl Estradiol 20 mcg/Drospirenone 3 mg	Beyaz 28, Dros-EE-Levomef 3-0.02-0.451, Drospirenone-EE 3-0.02 mg, Gianvi , Jasmiel, Nikki, Loryna, Lo-Zmandimine, Yaz	X	
Ethinyl Estradiol 20 mcg/Norethindrone 1 mg	Aurovelva 24 FE, Blosovi 24, Charlotte 24 FE chewable tab, Gemmily, Hailey 24 FE 1 mg-20 mcg, Junel FE 24, Larin 24 FE, Melodetta 24 FE chewable, Merzee, Mibelas, Microgestin 24 FE, Minastrin 24 FE Chewable, Noreth-Estrad-FE 1-0.02(24)-75, Tarina 24 FE, Taytulla	All but Taytulla are generic	
Ethinyl Estradiol 25 mcg/Norethindrone 0.8 mg	Generess FE, Kaitlib FE Chewable, Layolis FE Chewable, Norethin-Estra-Fe 0.8-0.025 mg	X	

Contraception Pharmacotherapy



OC Type/Regimen	Label Name	Generic	CA ADAP FORMULARY
BIPHASIC PRODUCTS			
Ethinyl Estradiol 10 mcg Days 1-26, None days 27-28/Norethindrone 1 mg Days 1-24, None Days 25-28	Lo Loestrin FE 1-10 tablet		
Ethinyl Estradiol 20 mcg Days 1-21, None Days 22-23, 10 mcg Days 24-28 /Desogestrel 0.15 mg Days 1-21	Azurette 28, Bekyree 28, Desogestr-Eth Estrad Eth Estra, Kariva 28, Mircette 28, Pimtrea, Simuya 28, Viorele 28, Volnea 0.15-0.02-0.01 mg	X	
TRIPHASIC PRODUCTS			
Ethinyl Estradiol 20 mcg Days 1-5, 30 mcg Days 6-12, 35 mcg Days 13-21, None Days 22-28/Norethindrone 1 mg days 1-21, None Days 22-28	Estrostep FE-28, Tilla FE 28, Tri-Lgest FE-28	X	
Ethinyl Estradiol 25 mcg Days 1-21, None Days 22-28/Norgestimate 0.18 mg days 1-7, 0.215 mg Days 8-14, 0.25 mg Days 15-21, None Days 22-28	Norg-EE 0.18-0.215-0.25/0.025, Tri-Lo-Estarylla, Ri-Lo-Marzia, Tri-Lo-Mili, Tri-Lo-Sprintec, Tri-Vylibra Lo	X	
Ethinyl Estradiol 25 mcg Days 1-21, None Days 22-28/Desogestrel 0.1 mg days 1-7, 0.125 mg Days 8-14, 0.15 mg Days 15-21, None Days 22-28	Caziant 28, Velivet 28	X	
Ethinyl Estradiol 30 mcg Days 1-6, 40 mcg Days 7-11, 30 mcg Days 12-21, None Days 22-28/Levonorgestrel 0.05 mg days 1-6, 0.075 mg Days 7-11, 0.125 mg Days 12-21, None Days 22-28	Enpresse-28, Levonest-28, Levonor-Eth Estrad Triphasic, Trivora-28	X	

Contraception Pharmacotherapy



OC Type/Regimen	Label Name	Generic	CA ADAP FORMULARY
TRIPHASIC PRODUCTS <i>continued...</i>			
Ethinyl Estradiol 35 mcg Days 1-21, None Days 22-28/Norgestimate 0.18 mg days 1-7, 0.215 mg Days 8-14, 0.25 mg Days 15-21, None Days 22-28	Norg-EE 0.18-0.215-0.25/0.035, Ortho Tri-Cyclen 28, Tri-Estarylla, Tri-Femynor 28, Tri-Linyah, Tri-Mili 28, Tri-Nymyo 28, Tri-Previfem, Tri-Sprintec, Tri-Vylibra28	X	
Ethinyl Estradiol 35 mcg Days 1-21, None Days 22-28/Norethindrone 0.5 mg days 1-7, 1 mg Days 8-16, 0.5 mg Days 17-21, None Days 22-28	Aranelle 28, Leena 28	X	
Ethinyl Estradiol 35 mcg Days 1-21, None Days 22-28/Norethindrone 0.5 mg days 1-7, 0.75 mg Days 8-14, 1 mg Days 15-21, None Days 22-28	Alyacen 7-7-7-28, Cyclafem 7-7-7-28, Dasetta 7/7/7-28, Nortrel 7-7-7-28, Nylia 7-7-7-28, Ortho-Novum 7-7-7-28, Pirmella 7-7-7-28	X	
FOUR-PHASIC PRODUCTS			
Estradiol Valerate 3 mg Days 1-2, 2 mg Days 3-24, 1 mg Days 25-26/Dienogest None Days 1-2, 2 mg Days 3-7, 3 mg Days 8-24, None Days 25-28	Natazia 28		

Contraception Pharmacotherapy



OC Type/Regimen	Label Name	Generic	CA ADAP FORMULARY
EXTENDED-CYCLE PRODUCTS			
Ethinyl Estradiol 20 mcg Days 1-84, /Levonorgestrel 0.1 mg Days 1-84, None Days 85-91	Amethia Lo, Camrese Lo, Lojaimiess 0.1-0.02-0.01 mg, Levono-E Estrad 0.10-0.02-0.01, Loseasonique	X	
Ethinyl Estradiol 20 mcg Days 1-42, 25 mcg Days 43-63, 30 mcg Days 64-84, 10 mcg Days 85-91 /Levonorgestrel 0.15 mg Days 1-84, None Days 85-91	Fayosim, Levonorg 0.15-EE 20-25-30 mcg, Quartette, Rivelsa	X	
Ethinyl Estradiol 30 mcg Days 1-84, None Days 85-91 /Levonorgestrel 0.15 mg Days 1-84, None Days 85-91	Iclevia, Introvale, Jolessa, Levonor-Eth Estrad 0.15-0.03, Setlakin	X	
Ethinyl Estradiol 30 mcg Days 1-84, 10 mcg Days 85-91/Levonorgestrel 0.15 mg Days 1-84, None Days 85-91	Ametheia, Ashlyna, Camrese, Daysee, Jaimiess, Levono-E Estrad 0.15-0.03-0.01, Seasonique, Simpesse	X	
CONTINUOUS-CYCLE PRODUCTS			
Ethinyl Estradiol 20 mcg /Levonorgestrel 90 mcg	Amethyst 90-20 mcg, Levonor-Eth Estra 0.09-0.02 mg	X	
PROGESTIN-ONLY PRODUCTS			
Drospirenone 4 mg	Slynd 4 mg		
Norethindrone 0.35 mg	Camila 0.35, Deblitane, Errin 0.35 mg, Heather 0.35, Incassia 0.35, Jencycla 0.35, Lyleq 0.35, Nora-Be, Norethindrone 0.35 mg, Norlyda 0.35 mg, Sharobel 0.35 mg, Tulana 0.35 mg	X	



Therapeutic Class Review

ASTHMA THERAPY

Asthma



- Asthma is a chronic disease of the lungs, characterized by episodes of recurrent wheezing, chest tightness, breathlessness, and coughing
 - Symptoms occur or worsen at night or with exercise, viral infection, exposure to allergens/irritants, changes in weather, hard laughing/crying, stress, or other factors.
- Goals of Asthma Management:
 - Achieve good symptom control and maintain normal activity levels
 - Minimize future risk of asthma-related mortality, exacerbations, persistent airflow limitation and side-effects of treatment.
- Consequences of uncontrolled asthma include:
 - Frequent emergency department (ED), urgent care, medical provider visits
 - Hospitalizations
 - Premature death
- Asthma in People Living with HIV (PLWH):
 - Studies show increased incidence of asthma among HIV-seropositive individuals, including those on HAART
 - HIV infection is associated with a high prevalence of respiratory symptoms such as cough, shortness of breath, and/or dyspnea on exertion.
 - Possible etiology is due to elevated serum IgE levels in PLWH

Asthma Treatment Guidelines



Stepwise Approach to Asthma Control from the 2020 GINA Guidelines- Controller Therapy			
Step	Age Group	Preferred Controller	Other Controller Options
Step 1: Symptom-driven or regular controller	≥ 12 years	<ul style="list-style-type: none"> As-needed low dose ICS-formoterol (unlabeled indication)† 	<ul style="list-style-type: none"> Low dose ICS whenever SABA is taken (unlabeled indication)
Step 2: One controller AND an as-needed reliever medication	≥ 12 years	<ul style="list-style-type: none"> Low dose ICS daily or <i>as needed</i> low dose ICS-formoterol (unlabeled indication)† 	<ul style="list-style-type: none"> Leukotriene modifier or low dose ICS whenever SABA is taken (unlabeled indication)
Step 3: Two controllers and an as-needed reliever medication	≥ 12 years	<ul style="list-style-type: none"> Low dose ICS/LABA 	<ul style="list-style-type: none"> Medium dose ICS OR low dose ICS + leukotriene modifier Sublingual immunotherapy (SLIT) may be considered in adults with allergic rhinitis, house dust mite sensitivity, and FEV₁ > 70% predicted
Step 4: Two controllers and an as-needed reliever medication	≥ 12 years	<ul style="list-style-type: none"> Medium dose ICS/LABA 	<ul style="list-style-type: none"> High dose ICS, add-on tiotropium, or add-on leukotriene modifier Sublingual immunotherapy (SLIT) may be considered in adults with allergic rhinitis, house dust mite sensitivity, and FEV₁ > 70% predicted
Step 5: Two controllers and an as-needed reliever medication	≥ 12 years	<ul style="list-style-type: none"> High dose ICS/LABA Refer for phenotypic assessment with or without add-on therapy (e.g., tiotropium, anti-IgE [omalizumab], anti-interleukin-5[IL5]/5R [mepolizumab, reslizumab, benralizumab], anti-IL4R [dupilumab]) 	<ul style="list-style-type: none"> Add-on low dose oral corticosteroid, considering adverse effects

Asthma Treatment Guidelines



Stepwise Approach to Asthma Control from 2020 GINA Guidelines-Reliever Therapy			
Age Group	Step	Preferred Reliever	Other Reliever Options
≥ 12 years	Steps 1 and 2	<ul style="list-style-type: none"> As-needed low dose ICS-formoterol (unlabeled indication)[†] 	<ul style="list-style-type: none"> As needed SABA
	Steps 3 through 5	<ul style="list-style-type: none"> As-needed low dose ICS-formoterol (unlabeled indication)[‡] 	

Asthma Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
INHALED CORTICOSTEROIDS		
Beclomethasone HFA inhalation aerosol (QVAR®)		
Budesonide inhalation powder (PULMICORT FLEXHALER®)		
Budesonide inhalation suspension (PULMICORT RESPULES®)	X	
Ciclesonide inhalation aerosol (ALVESCO®)		
Fluticasone furoate inhalation powder (ARNUITY®, ELLIPTA®)		
Fluticasone propionate inhalation aerosol (FLOVENT HFA®)		
Fluticasone propionate inhalation powder (ArmonAir®, Digihaler®)		
Fluticasone propionate inhalation powder (FLOVENT Diskus®)		
Mometasone Furoate inhalation aerosol (ASMANEX HFA®)		
Mometasone Furoate inhalation powder (ASMANEX TWISTHALER®)		
COMBINATION INHALED CORTICOSTEROIDS (ICS)/LONG-Acting Beta₂-Agonist (LABA)		
Budesonide/Formoterol Inhalation aerosol (SYMBICORT®)		
Fluticasone furoate/Vilanterol (BREO®, ELLIPTA®)		
Fluticasone propionate/Salmeterol inhalation aerosol (ADVAIR® HFA)		
Fluticasone propionate/Salmeterol inhalation powder (ADVAIR® DISKUS®)	X	
Fluticasone propionate/Salmeterol inhalation powder (AirDuo® Respiclick®, AirDuo Digihaler)	X	
Mometasone/Formoterol inhalation aerosol(DULERA®)		

Asthma Pharmacotherapy



Agent	Generic	CA ADAP FORMULARY
INHALED SHORT-ACTING BETA₂-AGONISTS (SABAs)		
Albuterol Inhalers (PROVENTIL, VENTOLIN, PROAIR)	X	
Levalbuterol HFA (XOPENEX)	X	
INHALED LONG-ACTING ANTIMUSCARINIC AGENT (LAMAs)		
Tiotropium (SPIRIVA)		
LEUKOTRIENE MODIFIERS		
Montelukast (SINGULAIR)	X	

References



1. American College of Obstetrics and Gynecology Bulletin No. 206 Use of hormonal contraception in women with coexisting medical conditions. *Obstetrics and Gynecology*. 2019; 133(6): 128-50. DOI: 10.1097/AOG.0000000000003332. Available at <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2019/02/use-of-hormonal-contraception-in-women-with-coexisting-medical-conditions>.
2. Clinical Pharmacology. Oral contraceptives, Combinations Drug Class Overview. Available at: <http://www.clinicalpharmacology.com>.
3. CDC. Contraception. Available at: <https://www.cdc.gov/reproductivehealth/contraception/index.htm#:~:text=Typical%20use%20failure%20rate%3A%204%25.&text=Combined%20oral%20contraceptives%E2%80%9494Also%20called,is%20prescribed%20by%20a%20doctor>.
4. FDA Drug Safety Communication: Updated information about the FDA-funded study on risk of blood clots in women taking birth control pills containing drospirenone. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm277346.htm>.
5. Centers for Disease Control and Prevention. Asthma prevalence in the US. Updated October 30, 2020. Available at: <https://www.cdc.gov/nchs/fastats/asthma.htm>.
6. Centers for Disease Control and Prevention. National surveillance of asthma: United States, 2001–2010. Available at: http://www.cdc.gov/nchs/data/series/sr_03/sr03_035.pdf.
7. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2020 pocket guide. Available at: <http://ginasthma.org>.
8. Kynnyk JA, Parsons JP, Para MF, Koletar SL, Diaz PT, Mastronarde JG. HIV and asthma, is there an association?. *Respir Med*. 2012;106(4):493-499. doi:10.1016/j.rmed.2011.12.017

Confidentiality statement



By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.